open access

Vol 21, No 4 (2016)
Special Issue Papers
Published online: 2016-07-01
Submitted: 2014-09-28
Get Citation

Review of carbon ion radiotherapy for skull base tumors (especially chordomas)

Jun-etsu Mizoe
DOI: 10.1016/j.rpor.2015.01.008
·
Rep Pract Oncol Radiother 2016;21(4):356-360.

open access

Vol 21, No 4 (2016)
Special Issue Papers
Published online: 2016-07-01
Submitted: 2014-09-28

Abstract

Aim

To review the clinical feasibility of carbon ion radiotherapy (C-ion RT) for skull base tumors, especially for chordomas which are often seen in the skull base area.

Background

Skull base tumors treated by C-ion RT consist of primary chordomas and chondrosarcomas, and enormously extended head and neck cancer with a histology of adenoid cystic carcinomas, adenocarcinomas and malignant melanomas. These tumors are located on anatomically complex sites where they are close to important normal tissues and therefore demand better physical dose distribution to avoid unnecessary doses for surrounding normal tissues. These tumors are also known as radio-resistant tumors for low linear energy transfer (LET) radiotherapy and show favorable results after treatment by high LET carbon ion radiotherapy.

Materials and methods

Biological reports of C-ions for the chordoma cell line, clinical results of C-ion RT for skull base tumors, dose comparative studies between two representative facilities and tumor control probability (TCP) of chordomas by C-ion RT were reviewed.

Results

C-ion RT for skull base tumors, especially for chordomas, shows favorable results of tumor control and acceptable complications. The C-ion dose of 57.36 gray equivalent (GyE)/16 fractions/4 weeks will deliver 90% of local control for chordomas. The limiting doses for surrounding normal tissues are clearly revealed. The dose difference between institutes was assumed within 10%.

Conclusions

C-ion RT is recommended for skull base tumors because of high LET characteristics and clinical results.

Abstract

Aim

To review the clinical feasibility of carbon ion radiotherapy (C-ion RT) for skull base tumors, especially for chordomas which are often seen in the skull base area.

Background

Skull base tumors treated by C-ion RT consist of primary chordomas and chondrosarcomas, and enormously extended head and neck cancer with a histology of adenoid cystic carcinomas, adenocarcinomas and malignant melanomas. These tumors are located on anatomically complex sites where they are close to important normal tissues and therefore demand better physical dose distribution to avoid unnecessary doses for surrounding normal tissues. These tumors are also known as radio-resistant tumors for low linear energy transfer (LET) radiotherapy and show favorable results after treatment by high LET carbon ion radiotherapy.

Materials and methods

Biological reports of C-ions for the chordoma cell line, clinical results of C-ion RT for skull base tumors, dose comparative studies between two representative facilities and tumor control probability (TCP) of chordomas by C-ion RT were reviewed.

Results

C-ion RT for skull base tumors, especially for chordomas, shows favorable results of tumor control and acceptable complications. The C-ion dose of 57.36 gray equivalent (GyE)/16 fractions/4 weeks will deliver 90% of local control for chordomas. The limiting doses for surrounding normal tissues are clearly revealed. The dose difference between institutes was assumed within 10%.

Conclusions

C-ion RT is recommended for skull base tumors because of high LET characteristics and clinical results.

Get Citation

Keywords

Carbon ion radiotherapy; Skull base tumor; Chordoma; TCP; High LET particle

About this article
Title

Review of carbon ion radiotherapy for skull base tumors (especially chordomas)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 4 (2016)

Pages

356-360

Published online

2016-07-01

DOI

10.1016/j.rpor.2015.01.008

Bibliographic record

Rep Pract Oncol Radiother 2016;21(4):356-360.

Keywords

Carbon ion radiotherapy
Skull base tumor
Chordoma
TCP
High LET particle

Authors

Jun-etsu Mizoe

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl